The endocannabinoid system and energy metabolism

被引:94
作者
Bellocchio, L.
Cervino, C.
Pasquali, R.
Pagotto, U. [1 ,2 ]
机构
[1] Univ Bologna, S Orsola M Malpighi Hosp, Endocrinol Unit, I-40138 Bologna, Italy
[2] Univ Bologna, S Orsola M Malpighi Hosp, Ctr Appl Biomed Res CRBA, Dept Internal Med & Gastroenterol, I-40138 Bologna, Italy
关键词
cannabinoid receptor type 1; hypothalamus; adipose tissue; obesity;
D O I
10.1111/j.1365-2826.2008.01728.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many different regulatory actions have been attributed to endocannabinoids, and their involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid receptors [cannabinoid receptor type 1 (CB1) and CB2] participate in the physiological modulation of many central and peripheral functions. The ability of the endocannabinoid system to control appetite, food intake and energy balance has recently received considerable attention, particularly in the light of the different modes of action underlying these functions. The endocannabinoid system modulates rewarding properties of food by acting at specific mesolimbic areas in the brain. In the hypothalamus, CB1 receptors and endocannabinoids are integrated components of the networks controlling appetite and food intake. Interestingly, the endocannabinoid system was recently shown to control several metabolic functions by acting on peripheral tissues such as adipocytes, hepatocytes, the gastrointestinal tract, the skeletal muscles and the endocrine pancreas. The relevance of the system is further strengthened by the notion that visceral obesity seems to be a condition in which an overactivation of the endocannabinoid system occurs, and therefore drugs interfering with this overactivation by blocking CB1 receptors are considered as potentially valuable candidates for the treatment of obesity and related cardiometabolic risk factors.
引用
收藏
页码:850 / 857
页数:8
相关论文
共 70 条
[1]   The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake [J].
Addy, Carol ;
Wright, Hamish ;
Van Laere, Koen ;
Gantz, Ira ;
Erondu, Ngozi ;
Musser, Bret J. ;
Lu, Kaifeng ;
Yuan, Jinyu ;
Sanabria-Bohorquez, Sandra M. ;
Stoch, Aubrey ;
Stevens, Cathy ;
Fong, Tung M. ;
De Lepeleire, Inge ;
Cilissen, Caroline ;
Cote, Josee ;
Rosko, Kim ;
Gendrano, Isaias N., III ;
Nguyen, Allison Martin ;
Gumbiner, Barry ;
Rothenberg, Paul ;
de Hoon, Jan ;
Bormans, Guy ;
Depre, Marleen ;
Eng, Wai-Si ;
Ravussin, Eric ;
Klein, Samuel ;
Blundell, John ;
Herman, Gary A. ;
Burns, H. Donald ;
Hargreaves, Richard J. ;
Wagner, John ;
Gottesdiener, Keith ;
Amatruda, John M. ;
Heymsfield, Steven B. .
CELL METABOLISM, 2008, 7 (01) :68-78
[2]   Cannabinoid type 1 receptor: Another arrow in the adipocytes' bow [J].
Bellocchio, L. ;
Cervino, C. ;
Vicennati, V. ;
Pasquali, R. ;
Pagotto, U. .
JOURNAL OF NEUROENDOCRINOLOGY, 2008, 20 :130-138
[3]   Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases [J].
Bellocchio, Luigi ;
Mancini, Giacomo ;
Vicennati, Valentina ;
Pasquali, Renato ;
Pagotto, Uberto .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) :586-591
[4]   Activation of cannabinoid CB1 receptors induces glucose intolerance in rats [J].
Bermúdez-Siva, FJ ;
Serrano, A ;
Diaz-Molina, FJ ;
Vera, IS ;
Juan-Pico, P ;
Nadal, A ;
Fuentes, E ;
de Fonseca, FR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 531 (1-3) :282-284
[5]  
BLUER M, 2006, DIABETES, V5, P3353
[6]   Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation [J].
Bouaboula, M ;
Hilairet, S ;
Marchand, J ;
Fajas, L ;
Le Fur, G ;
Casellas, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 517 (03) :174-181
[7]   Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide [J].
Cani, PD ;
Montoya, ML ;
Neyrinck, AM ;
Delzenne, NM ;
Lambert, DM .
BRITISH JOURNAL OF NUTRITION, 2004, 92 (05) :757-761
[8]   Effects of cannabinoid receptors on skeletal muscle oxidative pathways [J].
Cavuoto, P. ;
McAinch, A. J. ;
Hatzinikolas, G. ;
Cameron-Smith, D. ;
Wittert, G. A. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2007, 267 (1-2) :63-69
[9]   Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [J].
Christensen, Robin ;
Kristensen, Pernelle Kruse ;
Bartels, Else Marie ;
Blidda, Henning ;
Astrup, Arne .
LANCET, 2007, 370 (9600) :1706-1713
[10]  
Cota D, 2003, J CLIN INVEST, V112, P423, DOI [10.1172/JCI200317725, 10.1172/JCI17725]